Decoy Therapeutics Inc.
DCOY
$5.15
-$0.29-5.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -513.27% | 10.14% | 32.76% | 0.34% | -66.01% |
| Total Depreciation and Amortization | 245.45% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16,862.55% | -62.00% | -72.77% | -56.77% | -40.28% |
| Change in Net Operating Assets | -221.56% | -78.86% | -73.20% | 74.46% | 193.49% |
| Cash from Operations | -53.06% | -21.38% | 19.58% | 12.73% | 50.87% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 4.02% | 36.57% | 36.84% |
| Issuance of Common Stock | -- | 307.67% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,774.77% | 328.50% | -400.71% | 415.74% | 36.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 794.56% | 35,746.43% | 8.81% | 58.33% | 49.46% |